ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

ClinicalTrials.gov ID: NCT07282613

Public ClinicalTrials.gov record NCT07282613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

Study identification

NCT ID
NCT07282613
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
80 participants

Conditions and interventions

Interventions

  • CagriSema (Cagrilintide B and Semaglutide I) Drug
  • Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Drug

Drug

Eligibility (public fields only)

Age range
10 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2026
Primary completion
Sep 6, 2029
Completion
Mar 29, 2030
Last update posted
Mar 29, 2026

2026 – 2030

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Yale School of Medicine New Haven Connecticut 06511
Encore Medical Research Boynton Beach Boynton Beach Florida 33436
Nemours Chld Clnc Jacksonville Jacksonville Florida 32207
Innovus Clinical Kissimmee Florida 34741
D&H National Research Centers Tamarac Florida 33321
Clinical Research Trials of Florida Tampa Florida 33607
Columbus Research Foundation Columbus Georgia 31904
Eastside Bariatric and Gen Surg Snellville Georgia 30078
SIU Medicine Springfield Illinois 62702
Riley Hospital For Children Indianapolis Indiana 46202
University of Iowa Iowa City Iowa 52242
Great Lakes Research Inst. Southfield Michigan 48075
UBMD Pediatrics Buffalo New York 14203
NYU Langone Health New York New York 10016
Children's Hosptl Philadelphia Philadelphia Pennsylvania 19104
Monument Health Clinical Rsrch Rapid City South Dakota 57701
LifeDoc Health Memphis Tennessee 38115
Amir Ali Hassan, MD, PA Houston Texas 77089
Consano Clinical Research, LLC Shavano Park Texas 78231
UVA Health Systems Charlottesville Virginia 22903
Seattle Children's Research Institute Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07282613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07282613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →